You are here

Nat Rev Clin Oncol DOI:10.1038/s41571-021-00593-y

Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.

Publication TypeJournal Article
Year of Publication2022
AuthorsDutta, AK, Alberge, J-B, Sklavenitis-Pistofidis, R, Lightbody, ED, Getz, G, Ghobrial, IM
JournalNat Rev Clin Oncol
Date Published2022 Jan 11
ISSN1759-4782
Abstract

Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the past few years have led to improved outcomes and longer survival, MM remains largely incurable. Over the past decade, genomic analyses of patient samples have demonstrated that MM is not a single disease but rather a spectrum of haematological entities that all share similar clinical symptoms. Moreover, analyses of samples from monoclonal gammopathy of undetermined significance and smouldering MM have also shown the existence of genetic heterogeneity in precursor stages, in some cases remarkably similar to that of MM. This heterogeneity highlights the need for a greater dissection of underlying disease biology, especially the clonal diversity and molecular events underpinning MM at each stage to enable the stratification of individuals with a high risk of progression. Emerging single-cell sequencing technologies present a superlative solution to delineate the complexity of monoclonal gammopathy of undetermined significance, smouldering MM and MM. In this Review, we discuss how genomics has revealed novel insights into clonal evolution patterns of MM and provide examples from single-cell studies that are beginning to unravel the mutational and phenotypic characteristics of individual cells within the bone marrow tumour, immune microenvironment and peripheral blood. We also address future perspectives on clinical application, proposing that multi-omics single-cell profiling can guide early patient diagnosis, risk stratification and treatment strategies.

DOI10.1038/s41571-021-00593-y
Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35017721?dopt=Abstract

Alternate JournalNat Rev Clin Oncol
PubMed ID35017721